These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 7958382

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. The Sumatriptan Auto-Injector Study Group.
    Eur Neurol; 1991; 31(5):323-31. PubMed ID: 1653140
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study.
    Landy S, Munjal S, Brand-Schieber E, Rapoport AM.
    J Headache Pain; 2018 Aug 15; 19(1):70. PubMed ID: 30112725
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study.
    Rothner AD, Winner P, Nett R, Asgharnejad M, Laurenza A, Austin R, Peykamian M.
    Clin Ther; 2000 Dec 15; 22(12):1533-46. PubMed ID: 11192144
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Introduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice.
    Jensen K, Tfelt-Hansen P, Hansen EW, Krøis EH, Pedersen OS.
    Cephalalgia; 1995 Oct 15; 15(5):423-9. PubMed ID: 8536304
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.
    Cephalalgia; 1999 May 15; 19(4):232-40. PubMed ID: 10376168
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study.
    Ishkanian G, Blumenthal H, Webster CJ, Richardson MS, Ames M.
    Clin Ther; 2007 Jan 15; 29(1):99-109. PubMed ID: 17379050
    [Abstract] [Full Text] [Related]

  • 16. [18 months long-term analysis of effectiveness, safety and tolerance of sumatriptan s.c. in acute therapy of migraine attacks].
    Göbel H, Stolze H, Heinze A, Dworschak M, Heuss D, Christiani K, Lindner V.
    Nervenarzt; 1996 Jun 15; 67(6):471-83. PubMed ID: 8767202
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea.
    Schulman EA.
    Headache; 2012 Feb 15; 52(2):204-12. PubMed ID: 22229837
    [Abstract] [Full Text] [Related]

  • 19. Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment.
    Göbel H, Heinze A, Stolze H, Heinze-Kuhn K, Lindner V.
    Cephalalgia; 1999 Sep 15; 19(7):676-83; discussion 626. PubMed ID: 10524662
    [Abstract] [Full Text] [Related]

  • 20. Comparison of subcutaneous sumatriptan with usual acute treatments for migraine. French Sumatriptan Study Group.
    Boureau F, Chazot G, Emile J, Bertin L, d'Allens H.
    Eur Neurol; 1995 Sep 15; 35(5):264-9. PubMed ID: 8542914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.